Year: 2018
Type: article
Abstract: Amyotrophic lateral sclerosis (ALS) is a devastating and fatal motor neuron disease. Diagnosis typically occurs in the fifth decade of life and the disease progresses rapidly leading to death within ~ 2-5 years of symptomatic onset. There is no cure, and the few available treatments offer only a modest extension in patient survival. A protein central to ALS is the nuclear RNA/DNA-binding protein, TDP-43. In > 95% of ALS patients, TDP-43 is cleared from the nucleus and forms phosphorylated protein aggregates in the cytoplasm of affected neurons and glia. We recently defined that poly(ADP-ribose) (PAR) activity regulates TDP-43-associated toxicity. PAR is a posttranslational modification that is attached to target proteins by PAR polymerases (PARPs). PARP-1 and PARP-2 are the major enzymes that are active in the nucleus. Here, we uncovered that the motor neurons of the ALS spinal cord were associated with elevated nuclear PAR, suggesting elevated PARP activity. Veliparib, a small-molecule inhibitor of nuclear PARP-1/2, mitigated the formation of cytoplasmic TDP-43 aggregates in mammalian cells. In primary spinal-cord cultures from rat, Veliparib also inhibited TDP-43-associated neuronal death. These studies uncover that PAR activity is misregulated in the ALS spinal cord, and a small-molecular inhibitor of PARP-1/2 activity may have therapeutic potential in the treatment of ALS and related disorders associated with abnormal TDP-43 homeostasis.
Language: English
Subfield: Clinical Neurology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,790
Funders: ALS Association, Glenn Foundation for Medical Research, Johns Hopkins University, Target ALS, National Institutes of Health, National Institute on Aging, National Institute of General Medical Sciences, National Institute of Neurological Disorders and Stroke, Robert Packard Center for ALS Research, Johns Hopkins University, Carrie E. and Lena V. Glenn Foundation
Awards: Ataxin-2 as a genetic risk factor for ALS: New insights into neurodegeneration, Epigenetic Editing of Mutant C9orf72, Molecular Genetic Insight into Neurodegenerative Disease from Drosophila, Cytohesins, ARF GTP'ases and Neurodegeneration, Alzheimer's Disease Core Center, Frontotemporal Dementias: Genotypes and Phenotypes, Defining mechanisms of AAA+ disaggregases, ERAD genes that suppress neurodegeneration, AMPK, metabolism and ALS, Exploring and enhancing Karyopherin beta-2 disaggregate activity
OpenAlex ID: W2889245756
